 Join our Research Revisited event on the YouScreen study
Join us on Tuesday 30 September for the first in our new series of Research Revisited events. We'll be looking back at the YouScreen study which took place in 2021 and was the largest self-sampling cervical screening clinical trial.
We'll reflect on the crucial role the questions raised during the REC and Confidentiality Advisory Group (CAG) review process played on the success of the trial, which led to the recent government decision to rollout self-sampling kits for people who don't attend regular screening.
This is part of a new series of events where we will revisit studies reviewed by our RECs and CAG, and learn about the real world impact of the research they approved.
 Final spaces available for our research transparency webinar
We've got nearly 1,000 people signed up for our research transparency webinar on 2 October, which will focus on sharing research results with participants.
The event will cover what you need to know about transparency and the new clinical trials regulations which come into effect in April 2026.
Don't miss out on the last few remaining tickets!
Coming soon – final clinical trials regulations guidance
Next week, we’ll be publishing our final guidance to accompany the updated clinical trials regulations.
Thank you to everyone who shared their thoughts and comments on our earlier versions of the guidance.
The final guidance should be used by researchers and sponsors to update their policies and processes ahead of the amended regulations coming into force on 28 April 2026.
Sign up to our Clinical Trials update for the latest news and updates on the upcoming changes to the regulations.
 Our response to recent reports on commercial and non-commercial research
Last week, the Association of Medical Research Charities (AMRC) and Wellcome published a report which showcased a key strength of UK clinical research – our uniquely interconnected research system, supported by both commercial and non-commercial funding. We shared our thoughts on how this delivers enormous benefits for patients in the UK and around the world, as well as making a major contribution to the UK economy.
UK international competitiveness was also highlighted in a new report from the Association of British Pharmaceutical Industries (ABPI) on the factors that drive commercial clinical trial investment.
It gives insight into what is needed for the UK to become the number one life sciences economy in Europe by 2030.
Read our response to hear how our work as part of the UK Clinical Research Delivery (UK CRD) programme supports this.
 Study-wide review criteria: information governance update
As part of our work to support the UK Clinical Research Delivery (UKCRD) programme, to reduce duplication of activity that can be done once per study during study set-up, we have updated the information governance section (section 5.1) of the UK study-wide governance review criteria.
The study-wide governance review criteria describe the standards against which research applications are reviewed in all four nations of the UK.
|
